Global IBS-C Drug Sales Market Report 2021

1 IBS-C Drug Market Overview

• 1.1 IBS-C Drug Product Scope
• 1.2 IBS-C Drug Segment by Type
  • 1.2.1 Global IBS-C Drug Sales by Type (2016 & 2021 & 2027)
  • 1.2.2 Linaclotide
  • 1.2.3 Lubiprostone
  • 1.2.4 Osmotic Laxatives
  • 1.2.5 Stimulant Laxatives
  • 1.2.6 Other
• 1.3 IBS-C Drug Segment by Application
  • 1.3.1 Global IBS-C Drug Sales Comparison by Application (2016 & 2021 & 2027)
  • 1.3.2 Hospital Pharmacies
  • 1.3.3 Retail Pharmacies
  • 1.3.4 Online Pharmacies
• 1.4 IBS-C Drug Market Estimates and Forecasts (2016-2027)
  • 1.4.1 Global IBS-C Drug Market Size in Value Growth Rate (2016-2027)
  • 1.4.2 Global IBS-C Drug Market Size in Volume Growth Rate (2016-2027)
  • 1.4.3 Global IBS-C Drug Price Trends (2016-2027)

2 IBS-C Drug Estimates and Forecasts by Region

• 2.1 Global IBS-C Drug Market Size by Region: 2016 VS 2021 VS 2027
• 2.2 Global IBS-C Drug Retrospective Market Scenario by Region (2016-2021)
  • 2.2.1 Global IBS-C Drug Sales Market Share by Region (2016-2021)
  • 2.2.2 Global IBS-C Drug Revenue Market Share by Region (2016-2021)
• 2.3 Global IBS-C Drug Market Estimates and Forecasts by Region (2022-2027)
  • 2.3.1 Global IBS-C Drug Sales Estimates and Forecasts by Region (2022-2027)
  • 2.3.2 Global IBS-C Drug Revenue Forecast by Region (2022-2027)
• 2.4 Geographic Market Analysis: Market Facts & Figures
  • 2.4.1 North America IBS-C Drug Estimates and Projections (2016-2027)
  • 2.4.2 Europe IBS-C Drug Estimates and Projections (2016-2027)
  • 2.4.3 China IBS-C Drug Estimates and Projections (2016-2027)
  • 2.4.4 Japan IBS-C Drug Estimates and Projections (2016-2027)
  • 2.4.5 Southeast Asia IBS-C Drug Estimates and Projections (2016-2027)
  • 2.4.6 India IBS-C Drug Estimates and Projections (2016-2027)

3 Global IBS-C Drug Competition Landscape by Players

• 3.1 Global Top IBS-C Drug Players by Sales (2016-2021)
• 3.2 Global Top IBS-C Drug Players by Revenue (2016-2021)
• 3.3 Global IBS-C Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in IBS-C Drug as of 2020)
• 3.4 Global IBS-C Drug Average Price by Company (2016-2021)
• 3.5 Manufacturers IBS-C Drug Manufacturing Sites, Area Served, Product Type
• 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global IBS-C Drug Market Size by Type

• 4.1 Global IBS-C Drug Historic Market Review by Type (2016-2021)
  • 4.1.1 Global IBS-C Drug Sales Market Share by Type (2016-2021)
  • 4.1.2 Global IBS-C Drug Revenue Market Share by Type (2016-2021)
  • 4.1.3 Global IBS-C Drug Price by Type (2016-2021)
• 4.2 Global IBS-C Drug Market Estimates and Forecasts by Type (2022-2027)
  • 4.2.1 Global IBS-C Drug Sales Forecast by Type (2022-2027)
  • 4.2.2 Global IBS-C Drug Revenue Forecast by Type (2022-2027)
  • 4.2.3 Global IBS-C Drug Price Forecast by Type (2022-2027)

5 Global IBS-C Drug Market Size by Application

• 5.1 Global IBS-C Drug Historic Market Review by Application (2016-2021)
  • 5.1.1 Global IBS-C Drug Sales Market Share by Application (2016-2021)
  • 5.1.2 Global IBS-C Drug Revenue Market Share by Application (2016-2021)
  • 5.1.3 Global IBS-C Drug Price by Application (2016-2021)
• 5.2 Global IBS-C Drug Market Estimates and Forecasts by Application (2022-2027)
  • 5.2.1 Global IBS-C Drug Sales Forecast by Application (2022-2027)
  • 5.2.2 Global IBS-C Drug Revenue Forecast by Application (2022-2027)
  • 5.2.3 Global IBS-C Drug Price Forecast by Application (2022-2027)

6 North America IBS-C Drug Market Facts & Figures

• 6.1 North America IBS-C Drug Sales by Company
  • 6.1.1 North America IBS-C Drug Sales by Company (2016-2021)
  • 6.1.2 North America IBS-C Drug Revenue by Company (2016-2021)
• 6.2 North America IBS-C Drug Sales Breakdown by Type
  • 6.2.1 North America IBS-C Drug Sales Breakdown by Type (2016-2021)
  • 6.2.2 North America IBS-C Drug Sales Breakdown by Type (2022-2027)
• 6.3 North America IBS-C Drug Sales Breakdown by Application
  • 6.3.1 North America IBS-C Drug Sales Breakdown by Application (2016-2021)
  • 6.3.2 North America IBS-C Drug Sales Breakdown by Application (2022-2027)

7 Europe IBS-C Drug Market Facts & Figures

• 7.1 Europe IBS-C Drug Sales by Company
  • 7.1.1 Europe IBS-C Drug Sales by Company (2016-2021)
  • 7.1.2 Europe IBS-C Drug Revenue by Company (2016-2021)
• 7.2 Europe IBS-C Drug Sales Breakdown by Type
  • 7.2.1 Europe IBS-C Drug Sales Breakdown by Type (2016-2021)
  • 7.2.2 Europe IBS-C Drug Sales Breakdown by Type (2022-2027)
• 7.3 Europe IBS-C Drug Sales Breakdown by Application
  • 7.3.1 Europe 145 Sales Breakdown by Application (2016-2021)
  • 7.3.2 Europe 145 Sales Breakdown by Application (2022-2027)

8 China IBS-C Drug Market Facts & Figures

• 8.1 China IBS-C Drug Sales by Company
  • 8.1.1 China IBS-C Drug Sales by Company (2016-2021)
  • 8.1.2 China IBS-C Drug Revenue by Company (2016-2021)
• 8.2 China IBS-C Drug Sales Breakdown by Type
  • 8.2.1 China IBS-C Drug Sales Breakdown by Type (2016-2021)
  • 8.2.2 China IBS-C Drug Sales Breakdown by Type (2022-2027)
• 8.3 China IBS-C Drug Sales Breakdown by Application
  • 8.3.1 China 174 Sales Breakdown by Application (2016-2021)
  • 8.3.2 China 174 Sales Breakdown by Application (2022-2027)

9 Japan IBS-C Drug Market Facts & Figures

• 9.1 Japan IBS-C Drug Sales by Company
  • 9.1.1 Japan IBS-C Drug Sales by Company (2016-2021)
  • 9.1.2 Japan IBS-C Drug Revenue by Company (2016-2021)
• 9.2 Japan IBS-C Drug Sales Breakdown by Type
  • 9.2.1 Japan IBS-C Drug Sales Breakdown by Type (2016-2021)
  • 9.2.2 Japan IBS-C Drug Sales Breakdown by Type (2022-2027)
• 9.3 Japan IBS-C Drug Sales Breakdown by Application
  • 9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
  • 9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)

10 Southeast Asia IBS-C Drug Market Facts & Figures

• 10.1 Southeast Asia IBS-C Drug Sales by Company
  • 10.1.1 Southeast Asia IBS-C Drug Sales by Company (2016-2021)
  • 10.1.2 Southeast Asia IBS-C Drug Revenue by Company (2016-2021)
• 10.2 Southeast Asia IBS-C Drug Sales Breakdown by Type
  • 10.2.1 Southeast Asia IBS-C Drug Sales Breakdown by Type (2016-2021)
  • 10.2.2 Southeast Asia IBS-C Drug Sales Breakdown by Type (2022-2027)
• 10.3 Southeast Asia IBS-C Drug Sales Breakdown by Application
  • 10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
  • 10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)

11 India IBS-C Drug Market Facts & Figures

• 11.1 India IBS-C Drug Sales by Company
  • 11.1.1 India IBS-C Drug Sales by Company (2016-2021)
  • 11.1.2 India IBS-C Drug Revenue by Company (2016-2021)
• 11.2 India IBS-C Drug Sales Breakdown by Type
  • 11.2.1 India IBS-C Drug Sales Breakdown by Type (2016-2021)
  • 11.2.2 India IBS-C Drug Sales Breakdown by Type (2022-2027)
• 11.3 India IBS-C Drug Sales Breakdown by Application
  • 11.3.1 India IBS-C Drug Sales Breakdown by Application (2016-2021)
  • 11.3.2 India IBS-C Drug Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in IBS-C Drug Business

• 12.1 Catalent Pharmaceuticals Solutions
  • 12.1.1 Catalent Pharmaceuticals Solutions Corporation Information
  • 12.1.2 Catalent Pharmaceuticals Solutions Business Overview
  • 12.1.3 Catalent Pharmaceuticals Solutions IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.1.4 Catalent Pharmaceuticals Solutions IBS-C Drug Products Offered
  • 12.1.5 Catalent Pharmaceuticals Solutions Recent Development
• 12.2 Nestle
  • 12.2.1 Nestle Corporation Information
  • 12.2.2 Nestle Business Overview
  • 12.2.3 Nestle IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.2.4 Nestle IBS-C Drug Products Offered
  • 12.2.5 Nestle Recent Development
• 12.3 Abbott Laboratories
  • 12.3.1 Abbott Laboratories Corporation Information
  • 12.3.2 Abbott Laboratories Business Overview
  • 12.3.3 Abbott Laboratories IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.3.4 Abbott Laboratories IBS-C Drug Products Offered
  • 12.3.5 Abbott Laboratories Recent Development
• 12.4 Synergy Pharmaceuticals
  • 12.4.1 Synergy Pharmaceuticals Corporation Information
  • 12.4.2 Synergy Pharmaceuticals Business Overview
  • 12.4.3 Synergy Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.4.4 Synergy Pharmaceuticals IBS-C Drug Products Offered
  • 12.4.5 Synergy Pharmaceuticals Recent Development
• 12.5 Sucampo Pharmaceuticals
  • 12.5.1 Sucampo Pharmaceuticals Corporation Information
  • 12.5.2 Sucampo Pharmaceuticals Business Overview
  • 12.5.3 Sucampo Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.5.4 Sucampo Pharmaceuticals IBS-C Drug Products Offered
  • 12.5.5 Sucampo Pharmaceuticals Recent Development
• 12.6 Novartis Pharma
  • 12.6.1 Novartis Pharma Corporation Information
  • 12.6.2 Novartis Pharma Business Overview
  • 12.6.3 Novartis Pharma IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.6.4 Novartis Pharma IBS-C Drug Products Offered
  • 12.6.5 Novartis Pharma Recent Development
• 12.7 Astellas Pharmaceuticals
  • 12.7.1 Astellas Pharmaceuticals Corporation Information
  • 12.7.2 Astellas Pharmaceuticals Business Overview
  • 12.7.3 Astellas Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.7.4 Astellas Pharmaceuticals IBS-C Drug Products Offered
  • 12.7.5 Astellas Pharmaceuticals Recent Development
• 12.8 Ardelyx
  • 12.8.1 Ardelyx Corporation Information
  • 12.8.2 Ardelyx Business Overview
  • 12.8.3 Ardelyx IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.8.4 Ardelyx IBS-C Drug Products Offered
  • 12.8.5 Ardelyx Recent Development
• 12.9 Synthetic Biologics
  • 12.9.1 Synthetic Biologics Corporation Information
  • 12.9.2 Synthetic Biologics Business Overview
  • 12.9.3 Synthetic Biologics IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.9.4 Synthetic Biologics IBS-C Drug Products Offered
  • 12.9.5 Synthetic Biologics Recent Development
• 12.10 Teva Pharmaceutical Industries
  • 12.10.1 Teva Pharmaceutical Industries Corporation Information
  • 12.10.2 Teva Pharmaceutical Industries Business Overview
  • 12.10.3 Teva Pharmaceutical Industries IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.10.4 Teva Pharmaceutical Industries IBS-C Drug Products Offered
  • 12.10.5 Teva Pharmaceutical Industries Recent Development
• 12.11 Bama-Geve
  • 12.11.1 Bama-Geve Corporation Information
  • 12.11.2 Bama-Geve Business Overview
  • 12.11.3 Bama-Geve IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.11.4 Bama-Geve IBS-C Drug Products Offered
  • 12.11.5 Bama-Geve Recent Development
• 12.12 Ferring BV
  • 12.12.1 Ferring BV Corporation Information
  • 12.12.2 Ferring BV Business Overview
  • 12.12.3 Ferring BV IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.12.4 Ferring BV IBS-C Drug Products Offered
  • 12.12.5 Ferring BV Recent Development
• 12.13 Ironwood Pharmaceuticals
  • 12.13.1 Ironwood Pharmaceuticals Corporation Information
  • 12.13.2 Ironwood Pharmaceuticals Business Overview
  • 12.13.3 Ironwood Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.13.4 Ironwood Pharmaceuticals IBS-C Drug Products Offered
  • 12.13.5 Ironwood Pharmaceuticals Recent Development
• 12.14 Salix Pharmaceuticals
  • 12.14.1 Salix Pharmaceuticals Corporation Information
  • 12.14.2 Salix Pharmaceuticals Business Overview
  • 12.14.3 Salix Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.14.4 Salix Pharmaceuticals IBS-C Drug Products Offered
  • 12.14.5 Salix Pharmaceuticals Recent Development
• 12.15 Norgine
  • 12.15.1 Norgine Corporation Information
  • 12.15.2 Norgine Business Overview
  • 12.15.3 Norgine IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.15.4 Norgine IBS-C Drug Products Offered
  • 12.15.5 Norgine Recent Development
• 12.16 Prometheus Laboratories
  • 12.16.1 Prometheus Laboratories Corporation Information
  • 12.16.2 Prometheus Laboratories Business Overview
  • 12.16.3 Prometheus Laboratories IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.16.4 Prometheus Laboratories IBS-C Drug Products Offered
  • 12.16.5 Prometheus Laboratories Recent Development
• 12.17 Actavis Nordic
  • 12.17.1 Actavis Nordic Corporation Information
  • 12.17.2 Actavis Nordic Business Overview
  • 12.17.3 Actavis Nordic IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.17.4 Actavis Nordic IBS-C Drug Products Offered
  • 12.17.5 Actavis Nordic Recent Development
• 12.18 Albireo Pharma
  • 12.18.1 Albireo Pharma Corporation Information
  • 12.18.2 Albireo Pharma Business Overview
  • 12.18.3 Albireo Pharma IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.18.4 Albireo Pharma IBS-C Drug Products Offered
  • 12.18.5 Albireo Pharma Recent Development
• 12.19 Yuhan Corp
  • 12.19.1 Yuhan Corp Corporation Information
  • 12.19.2 Yuhan Corp Business Overview
  • 12.19.3 Yuhan Corp IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.19.4 Yuhan Corp IBS-C Drug Products Offered
  • 12.19.5 Yuhan Corp Recent Development
• 12.20 Astrazeneca
  • 12.20.1 Astrazeneca Corporation Information
  • 12.20.2 Astrazeneca Business Overview
  • 12.20.3 Astrazeneca IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.20.4 Astrazeneca IBS-C Drug Products Offered
  • 12.20.5 Astrazeneca Recent Development
• 12.21 The Menarini Group
  • 12.21.1 The Menarini Group Corporation Information
  • 12.21.2 The Menarini Group Business Overview
  • 12.21.3 The Menarini Group IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.21.4 The Menarini Group IBS-C Drug Products Offered
  • 12.21.5 The Menarini Group Recent Development
• 12.22 Ono Pharmaceutical
  • 12.22.1 Ono Pharmaceutical Corporation Information
  • 12.22.2 Ono Pharmaceutical Business Overview
  • 12.22.3 Ono Pharmaceutical IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
  • 12.22.4 Ono Pharmaceutical IBS-C Drug Products Offered
  • 12.22.5 Ono Pharmaceutical Recent Development

13 IBS-C Drug Manufacturing Cost Analysis

• 13.1 IBS-C Drug Key Raw Materials Analysis
  • 13.1.1 Key Raw Materials
  • 13.1.2 Key Raw Materials Price Trend
  • 13.1.3 Key Suppliers of Raw Materials
• 13.2 Proportion of Manufacturing Cost Structure
• 13.3 Manufacturing Process Analysis of IBS-C Drug
• 13.4 IBS-C Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

• 14.1 Marketing Channel
• 14.2 IBS-C Drug Distributors List
• 14.3 IBS-C Drug Customers

15 Market Dynamics

• 15.1 IBS-C Drug Market Trends
• 15.2 IBS-C Drug Drivers
• 15.3 IBS-C Drug Market Challenges
• 15.4 IBS-C Drug Market Restraints

16 Research Findings and Conclusion

17 Appendix

• 17.1 Research Methodology
  • 17.1.1 Methodology/Research Approach
  • 17.1.2 Data Source
• 17.2 Author List